Browsing by Yonsei Author : Paik, Soon Myung

eperson profile image
Name:
Paik, Soon Myung [백순명]
orcid http://orcid.org/0000-0001-9688-6480
Department :
College of Medicine (의과대학) - BioMedical Science Institute (의생명과학부)
Scopus ID :
Scopus (34977365100)

Keyword Cloud

Researcher Network

Showing results 1 to 50 of 55

This table browses all dspace content
Issue DateTitleJournal Title
2023Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancerJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
2023Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41BREAST CANCER RESEARCH AND TREATMENT
2023Fusobacterium nucleatum induces a tumor microenvironment with diminished adaptive immunity against colorectal cancers FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
2022Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bevJOURNAL OF CLINICAL ONCOLOGY
2021Association between Fusobacterium nucleatum and patient prognosis in metastatic colon cancer SCIENTIFIC REPORTS
2021Genomic landscape of extraordinary responses in metastatic breast cancer COMMUNICATIONS BIOLOGY
2021Dynamic changes in circulating PD-1(+)CD8(+)T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancerEUROPEAN JOURNAL OF CANCER
2020Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck BRITISH JOURNAL OF CANCER
2020An Improved, Assay Platform Agnostic, Absolute Single Sample Breast Cancer Subtype Classifier CANCERS
2020Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831 JNCI CANCER SPECTRUM
2020Earlier-Phased Cancer Immunity Cycle Strongly Influences Cancer Immunity in Operable Never-Smoker Lung Adenocarcinoma ISCIENCE
2020Echocardiographic parameters determining cardiovascular outcomes in patients after acute ischemic strokeINTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING
2020Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer SCIENTIFIC REPORTS
2020Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer EXPERIMENTAL AND MOLECULAR MEDICINE
2020Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer BMC CANCER
2020Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical TrialJAMA ONCOLOGY
2020NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+ JOURNAL OF CLINICAL ONCOLOGY
2020Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapyINTERNATIONAL JOURNAL OF CANCER
2019PI3K/AKT/β-Catenin Signaling Regulates Vestigial-Like 1 Which Predicts Poor Prognosis and Enhances Malignant Phenotype in Gastric Cancer CANCERS
2019Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast CancerJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
2019A therapeutic strategy for chemotherapy-resistant gastric cancer via destabilization of both β-catenin and ras CANCERS
2019Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trialLANCET ONCOLOGY
2018Bcl-2-dependent synthetic lethal interaction of the IDF-11774 with the V0 subunit C of vacuolar ATPase (ATP6V0C) in colorectal cancerBritish Journal of Cancer
2018Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations PLoS One
2018Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab Pharmacogenetics and Genomics
201821-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology Breast Cancer Research and Treatment
2018Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology)BRITISH JOURNAL OF CANCER
2018Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotationLUNG CANCER
2018Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth GENOME RESEARCH
2018Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells with Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRTGASTROENTEROLOGY
2018Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity informationANNALS OF ONCOLOGY
2018AIRVF: a filtering toolbox for precise variant calling in Ion Torrent sequencingBIOINFORMATICS
2017Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial JAMA ONCOLOGY
2017Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further ResearchADVANCES IN ANATOMIC PATHOLOGY
2017The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40ANNALS OF SURGICAL ONCOLOGY
201721-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine TherapyJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
2017Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer ONCOTARGET
2017Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinomaANNALS OF ONCOLOGY
2017Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype ONCOTARGET
2017Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancerBREAST CANCER RESEARCH AND TREATMENT
2016Prognostic Tests for Estrogen Receptor-Positive Breast Cancer: Need for Global Consideration and Further EvolutionJAMA ONCOLOGY
2016Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial JAMA ONCOLOGY
2016Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative ONCOTARGET
2016Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy ONCOGENESIS
2016CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer NEW ENGLAND JOURNAL OF MEDICINE
2015Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma ONCOTARGET
2015Prospective Validation of a 21-Gene Expression Assay in Breast Cancer NEW ENGLAND JOURNAL OF MEDICINE
2015Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma MOLECULAR CANCER THERAPEUTICS
2015Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trialLANCET ONCOLOGY
2015Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trialJOURNAL OF CLINICAL ONCOLOGY
12

Browse

Links